McKesson Co. (NYSE:MCK) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp reduced its holdings in shares of McKesson Co. (NYSE:MCK) by 7.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,506 shares of the company’s stock after selling 298 shares during the quarter. Hancock Whitney Corp’s holdings in McKesson were worth $387,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in shares of McKesson by 173.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 520,286 shares of the company’s stock worth $69,016,000 after purchasing an additional 329,814 shares in the last quarter. Brown Advisory Inc. lifted its holdings in shares of McKesson by 13.4% in the third quarter. Brown Advisory Inc. now owns 4,094 shares of the company’s stock valued at $543,000 after purchasing an additional 484 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of McKesson in the third quarter valued at approximately $6,679,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of McKesson in the third quarter valued at approximately $600,000. Finally, Ancora Advisors LLC lifted its holdings in McKesson by 269.4% during the third quarter. Ancora Advisors LLC now owns 17,008 shares of the company’s stock worth $2,257,000 after acquiring an additional 12,404 shares during the period. Institutional investors and hedge funds own 86.60% of the company’s stock.

In related news, EVP Lori A. Schechter sold 7,700 shares of the business’s stock in a transaction dated Wednesday, January 16th. The stock was sold at an average price of $122.96, for a total transaction of $946,792.00. Following the completion of the transaction, the executive vice president now directly owns 10,000 shares in the company, valued at $1,229,600. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.87% of the stock is currently owned by insiders.

Shares of NYSE MCK traded up $1.16 during mid-day trading on Monday, hitting $117.21. The company had a trading volume of 1,038,615 shares, compared to its average volume of 1,564,436. The stock has a market cap of $22.35 billion, a PE ratio of 9.29, a price-to-earnings-growth ratio of 1.16 and a beta of 1.24. McKesson Co. has a 1 year low of $106.11 and a 1 year high of $160.84. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.57 and a current ratio of 1.02.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Thursday, January 31st. The company reported $3.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.18 by $0.22. The company had revenue of $56.21 billion during the quarter, compared to analysts’ expectations of $55.27 billion. McKesson had a positive return on equity of 27.83% and a negative net margin of 0.15%. During the same period in the previous year, the business earned $3.41 earnings per share. On average, sell-side analysts predict that McKesson Co. will post 13.55 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 1.33%. The ex-dividend date was Thursday, February 28th. McKesson’s dividend payout ratio (DPR) is presently 12.36%.

A number of analysts recently commented on MCK shares. Zacks Investment Research lowered McKesson from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. ValuEngine lowered McKesson from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 5th. Barclays restated a “hold” rating and issued a $124.00 target price on shares of McKesson in a research note on Sunday, January 6th. UBS Group began coverage on McKesson in a research note on Thursday, January 17th. They issued a “neutral” rating and a $134.00 target price on the stock. Finally, Deutsche Bank upgraded McKesson from a “sell” rating to a “hold” rating and set a $175.00 target price on the stock in a research note on Friday, January 25th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $134.90.

COPYRIGHT VIOLATION WARNING: This report was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

McKesson Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

See Also: Diversification For Individual Investors

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with's FREE daily email newsletter.